Keine Internetverbindung – die gespeicherte Version der Seite wird angezeigt.

Scilex Holding Co…

USUSD
← Zum Screener

Scilex Holding Company (US:SCLX) — Biotechnology: Biological Products (No Diagnostic Substances). Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 1. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.

Über das Unternehmen

Website
scilexholding.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hauptsitz
PALO ALTO, United States
CEO
Dr. Henry H. Ji Ph.D.
Mitarbeiter
34
Ausstehende Aktien
8.49 Mio. Stand 2026-08-10
Streubesitz
5.69 Mio.
Marktkapitalisierung
31.02 Mio. USD
Insider
11.67%
Institutionelle Anleger
8.52%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Ausschüttungsquote
Verlust
FCF
−17.8 Mio. USD
FCF < 0
Schulden
28.8 Mio. USD
Dividendenserie
—
Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 30.06.2026 (letzter Bericht des Unternehmens).
Beschreibung

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.

Börsen und Ticker

BörseTickerWährungPreisTyp
US USA StocksSCLXUSD2.96 -15.19%Stammaktie

Kurs über 3 Monate

US:SCLX · USD
Tag mit Kursanstieg Tag mit Kursrückgang Ex-Dividenden-Tag ZahltagTag mit der Maus berühren / antippen — Eröffnungs-, Schluss-, Höchst- und Tiefstkurs

Dividenden

Keine Dividendenzahlungen gefunden (geprüft 10.10.2026). Das Unternehmen schüttet wahrscheinlich keine Dividenden aus.

Neuigkeiten diese Woche

Noch keine Nachrichten von der Website des Unternehmens.

Anzeige

Größte Anteilseigner

InhaberAnteilAktienBerichtsdatum
JI HENRY H (Officer and…≈8.02%680 8842024-10-31
Vanguard Capital Managem…3.55%301 2922026-06-30
SHAH JAISIM (Chief Execu…≈3.48%295 2152024-12-18
VANGUARD INDEX FUNDS-Van…2.56%217 5102026-06-30
CHUN JAY (Director)≈1.33%112 5112024-10-18
Blackrock Inc.1.29%109 4172026-06-30
VANGUARD INDEX FUNDS-Van…0.9%76 2302026-06-30
Vanguard Fiduciary Trust…0.54%45 8222026-06-30
Jacobs Levy Equity Manag…0.48%41 1632026-06-30
State Street Corporation0.42%35 3762026-06-30
UBS Group AG0.39%33 3762026-06-30
Renaissance Technologies…0.39%33 0642026-06-30
Citadel Advisors Llc0.32%27 4972026-06-30
WU YUE ALEXANDER (Direct…≈0.29%25 0002024-10-17
iShares Trust-iShares Mi…0.28%23 9352026-08-31
MA STEPHEN HOI (Chief Fi…≈0.27%22 8402024-10-16
Price (T.Rowe) Associate…0.25%20 9202026-06-30
Ashton Thomas Private We…0.22%18 4822026-06-30
-Price (T.Rowe) U.S. Equ…0.17%14 0202026-06-30
T. ROWE PRICE INDEX TRT,…0.08%6 9002026-06-30
VANGUARD Inst. INDEX Fd.…0.04%3 8052026-06-30
VANGUARD VALLEY FORGE FU…0.04%3 7472026-06-30
FOLLOWWILL DORMAN (Direc…≈0.03%2 3002024-10-18
LEMUS DAVID (Director)≈0.02%2 0002024-10-17
EQ Advisors Trust-1290 V…0.02%1 6832026-06-30
Brighthouse Funds Trust…0.01%6272026-06-30
STATE STREET Inst. INVES…0%1202026-06-30
SCILEX HOLDING CO (Benef…—244.45 Mio.2025-12-30